source
- BlossomHill and Latigo Biotherapeutics raise over 30% beyond IPO targetsTwo emerging biotech companies surpassed their initial public offering expectations on Friday, with both BlossomHill Therapeutics and Latigo Biotherapeutics raising at least 30% more capital than p…
- BioMarin halts development of BMN 401 after phase 3 missBioMarin Pharmaceutical announced it is ending all work on its experimental enzyme replacement therapy BMN 401 following a late‑stage trial that did not meet one of two primary goals in patients wi…